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Abstract 
Modelin-5-CONH2 (M5-NH2) is a synthetic antimicrobial peptide, which was found to show 
potent activity against Bacillus subtilis (Minimum lethal concentration = 8.47 µM) and to bind 
strongly to membranes of the organism (Kd = 10.44 µM). The peptide adopted high levels of 
amphiphilic α-helical structure in the presence of these membranes (> 50 %), which led to high 
levels of insertion (Δπ ≥ 8.0 mN m-1). M5-NH2 showed high affinity for anionic lipid (Kd = 7.46 
µM) and zwitterionic lipid (Kd = 14.7 µM), which drove insertion into membranes formed from 
these lipids (Δπ = 11.5 and 3.5 mN m-1, respectively). Neutron diffraction studies showed that M5-
NH2 inserted into B. subtilis membranes with its N-terminal residue, L16, located 5.5 Å from the 
membrane centre, in the acyl chain region of these membranes, and promoted a reduction in 
membrane thickness of circa 1.8 Å or 5 % of membrane width. Insertion into B. subtilis 
membranes by the peptide also promoted other effects associated with membrane thinning, 
including increases in membrane surface area (Cs-1 decreases) and fluidity (ΔGmix > 0 to ΔGmix < 
0). Membrane insertion and thinning by M5-NH2 induced high levels of lysis (> 55%), and it is 
speculated that the antibacterial action of the peptide may involve the toroidal pore, carpet or tilted-
type mechanism of membrane permeabilization. 
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Introduction 
The emergence of microbial pathogens with multiple drug resistance (MDR) has rendered 
bacterial infections as one of the leading global causes of mortality, precipitating a serious 
public health issue in countries across the world 1. Due to the gravity of the threat posed by 
MDR pathogens, the World Health Organization (WHO) has ranked MDR as a priority 
issue, which if not remedied, could usher a return to the pre-antibiotic era when many 
common diseases were untreatable 2. More recently, major reports by the WHO and the UK 
Government have called for harmonized, global action to counter the threat posed by MDR 
pathogens, which includes the identification of new antibiotics and the development of 
novel antimicrobial strategies 3, 4. Most recently, the WHO took the unprecedented step of 
publishing a list of the twelve MDR bacteria that pose the greatest threat to human health 
with the aim of catalysing the development of crucially needed, new antibiotics to kill these 
‘priority pathogens’ 5. For example, Acinetobacter baumannii is listed and whilst in the 
early 1970s, the organism was largely unknown and recognized as an opportunistic, 
nosocomial pathogen, primarily infecting critically ill or immunocompromised patients it 
was susceptible to most antibiotics.  By the 1990s, it was increasingly becoming established 
as an emergent, opportunistic pathogen with MDR 6 and today, this organism has acquired 
resistance to virtually all antibiotics capable of treating Gram-negative bacteria, including 
carbapenems, which are ‘last-line’ β-lactams used to treat infections caused by these 
organisms 7. More recently, strains of carbapenem-resistant A. baumannii have emerged 
with resistance to colistin, which, due to its neurotoxicity and nephrotoxicity, was 
considered to be the ‘last resort’ drug capable of treating infections caused by the organism 
8. Currently, carbapenem-resistant A. baumannii is regarded as the most difficult 
nosocomial pathogen to treat, which is reflected by its ‘critical’ priority and position at the 
top of the ‘priority pathogens’ list 5.  
The call by the WHO and UK Governments for global action to combat the threat of 
MDR pathogens proposes a number of interventions and a major example is the therapeutic 
development of antimicrobial peptides (AMPs) 3, 4. These peptides are endogenous 
antimicrobials that have been identified in living things across the eukaryotic kingdom and 
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have potent activity against not only bacteria, but also viruses, fungi, parasites and even 
cancer cells 9-12. A variety of resistance mechanisms to AMPs have been described in 
bacteria, which generally involve the inherent properties of these organisms rather than the 
acquisition of dedicated resistance genes 13. This intrinsic protection from AMPs is 
generally moderate in level and relatively non-specific in nature, which is reflected in the 
low frequency of resistant bacteria and the evolutionary persistence and success of these 
peptides 14. The evolution of bacterial resistance to AMPs has been demonstrated 
experimentally 15, but based on the pharmacodynamics of these peptides, it has been 
predicted that they are much less likely to select for resistant mutants in vivo than 
conventional antibiotics 16. Indeed, recent studies have suggested that the likelihood of 
bacteria developing resistance to AMPs is greatly reduced when they are exposed to 
synergistic combinations of these peptides, as would be the case in vivo 17. These 
observations have led to the generally held view that bacterial resistance to AMPs is 
unlikely to approach the levels observed for conventional antibiotics 9, 10, although this view 
has been questioned 15. Other advantages of AMPs include high potency and selectivity, a 
broad range of targets, potentially low toxicity and low accumulation in tissues. These are 
highly desirable properties in the development of therapeutically useful antimicrobial 
agents 18. However, the full commercial exploitation of AMPs has been hindered for a 
variety of reasons, primarily their high cost of manufacture and their strong tendency to 
undergo proteolytic degradation in vivo 10, 12. In response, concerted attempts to develop 
AMPs by producing analogues, mimics, and de novo, synthetic forms of these peptides 
have been undertaken and currently, a number of these molecules are in clinical trials and 
therapeutic use 9, 10, 12. 
A synthetic AMP with many of the properties needed for therapeutic development is 
modelin-5-CONH2 (M5-NH2), which is an α-helical peptide with anticancer activity 19-21 
and broad range antimicrobial action 20, 22-25 that is accompanied by negligible lysis of 
erythrocytes from humans and other mammals 26. The peptide is effective against a variety 
of Gram-negative bacteria, including clinical isolates 22, and its ability to kill the 
archetypical member of these organisms, Escherichia coli, has been well characterised, 
appearing to involve a carpet-type mechanism 24, 25. M5-NH2 also possesses activity against 
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Gram-positive bacteria 22, 23, Bacillus subtilis, which is generally taken as the model 
organism for this bacterial class and which forms the focus of the present study 27. The 
peptide was found to possess potent activity against this organism and a range of 
biophysical techniques, including neutron diffraction, lipid monolayers and CD 
spectroscopy, are used to investigate the antibacterial mechanism involved. This 
mechanism appears to involve the ability of anionic lipid in B. subtilis membranes to 
promote the adoption of high levels of amphiphilic α-helical structure by M5-NH2. This 
amphiphilic secondary structure then appears to drive the penetration, thinning and lysis of 
the organism’s membranes by the peptide.  It is speculated that this lysis involves one of 
the following mechanisms of action: toroidal pore, carpet and tilted-type.  
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Experimental  
Materials 
  M5-NH2 (KLAKKLAKLAKLAKAL-CONH2) and d-M5-NH2-L16 
(KLAKKLAKLAKLAKAL(d16)-CONH2) were supplied by Pepceuticals (Leicestershire, 
UK), and were purified by HPLC to purity greater than 95%, confirmed by MALDI mass 
spectrometry.  All buffers were prepared using ultra-pure water (resistivity 18 MΩ cm).  
The phospholipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) and 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) were purchased from 
Avanti Polar Lipids (Alabaster, AL).  Ringer’s solution (RS), Nutrient broth (NB) and 
Nutrient agar (NA) were purchased from Thermo Fisher Scientific (Leicestershire, UK). 
HPLC grade solvents were obtained from VWR International Ltd (Lutterworth, UK) and 
all other regents were purchased from Sigma-Aldrich Company Ltd. (Dorset, UK).  
 
Methods 
The theoretical analysis of M5-NH2. The sequence of M5-NH2 was modelled as a two-
dimensional axial projection assuming an angular periodicity of 100° according to the 
helical wheel analysis of Schiffer and Edmundson 28. The amphiphilicity of this α-helical 
arrangement was quantified as < µH >, according to hydrophobic moment methodology 
using a moving window of eleven residues and the normalized consensus hydrophobicity 
scale of Eisenberg 29. The potential of M5-NH2 to form a tilted peptide was investigated by 
amphiphilic profiling using - < µH >, with a moving window of seven residues and the 
normalized consensus hydrophobicity scale of Eisenberg 30.  
The antibacterial activity of M5-NH2. The antibacterial activity of M5-NH2 was 
determined using B. subtilis (strain NCIMB 1671), which was taken from a frozen stock (-
80 °C), inoculated into 10 ml aliquots of sterile NB and incubated in an orbital shaker (100 
rpm and 37˚C) until the exponential phase (OD = 0.6; λ = 600 nm) was reached. This culture 
was then centrifuged at 15000 × g and 4 °C for 10 min using a bench top centrifuge and the 
resultant cell pellet washed 3 times in 1 ml aliquots of 25% strength RS, before being 
resuspended in 1 ml of 25 % strength RS.  For the standard assay, these samples were 
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further diluted with 25 % strength RS to achieve a bacterial density of 106 CFU ml-1. Then, 
10 μl aliquots of these cell suspensions were taken, inoculated with 1 ml of M5-NH2 in RS 
to give final peptide concentrations of 3.90 μM to 1 M and incubated overnight at 37 °C.  
As a control, cultures of B. subtilis were similarly treated but in the absence of M5-NH2.  
After incubation, 10 µl aliquots of the control samples and bacterial cultures that had been 
treated with M5-NH2 were surface spread onto an NA plate and incubated at 37 °C for 12 
hours. After incubation, the plates were viewed and the lowest peptide concentration 
yielding no bacterial growth was identified as the minimal lethal concentration (MLC) of 
M5-NH2. These experiments were repeated 4 times and the average MLCs determined 25.   
The conformational analysis of M5-NH2. The conformational preferences of M5-NH2 in 
the presence of small unilamellar vesicles (SUVs), formed from POPE, POPG, or lipid 
mixtures, were analysed using a J-815 spectropolarimeter (Jasco, UK) at 20 °C with the 
vesicles acting as model B. subtilis membranes.  These SUVs acting as model B. subtilis 
membranes were formed from mixtures of POPG and POPE in the molar ratio 70:30 or 
total lipid extracts of the organism’s membranes, which were dissolved in chloroform. 
These various lipid solutions were then dried under N2 gas, vacuum-dried for 4 hours, and 
the resulting lipid films rehydrated using 1 × PBS (pH 7.5). Rehydrated samples were then 
vortexed for 5 min and the resulting lipid suspensions sonicated for 30 min using a Soniprep 
150 (ISTCP, USA) sonicator until clear, followed by three cycles of freeze-thawing. The 
resulting solutions of SUVs were then extruded 11 times through a 0.1 μm polycarbonate 
filter using an Avanti (UK) polar lipids mini-extruder apparatus and diluted 10-fold using 
1 × PBS (pH 7.5). These diluted SUVs were then mixed with stock M5-NH2 solution (final 
concentration of 0.1 mg ml-1) to give samples with a peptide:lipid molar ratio of 1:100. 
Both in the presence and absence of these SUVs, far-UV CD spectra were collected for 
M5-NH2, where four scans per sample were obtained using a 10 mm path-length cell. Each 
scan was performed over a wavelength range of 260 to 180 nm at 0.5 nm intervals 
employing a bandwidth of 1 nm and at a speed 50 nm min-1 31. For all spectra acquired, the 
baseline acquired in the absence of peptide was subtracted and the percentage α-helical 
content of M5-NH2 estimated using the CDSSTR method (protein reference set 3) from the 
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DichroWeb server 32. These experiments were repeated 4 times and the percentage α-
helicity was averaged.  
The interaction of M5-NH2 with lipid monolayers. Insertion experiments were carried out 
at constant area to quantify the interaction of M5-NH2 with lipid monolayers using a 601M 
Langmuir trough (Biolin Scientific\KSV NIMA, Coventry, UK). Chloroformic lipid 
solutions (1 mg ml-1), which contained POPE, POPG, mixtures of POPG and POPE in the 
molar ratio 70:30 or lipid extracts from membranes of B. subtilis, were spread drop-wise 
onto an air-buffer (1 × PBS, pH 7.4) interface using a Hamilton syringe. The solvent was 
allowed to evaporate and, then, monolayers were compressed by 2 moveable Derlin barriers 
with a velocity of 50 mm min-1 to a starting surface pressure of 30 mN m-1, which 
corresponds to that generated by the packing density of naturally occurring cell membranes 
33. Once the monolayer was stable at a starting pressure of 30 mN m-1, M5-NH2 was injected 
underneath the monolayer to give a final peptide concentration of 6 µM in the subphase (1 
× PBS pH 7.4). The surface area of monolayers was kept constant via a built-in controlled 
feedback system, and surface pressure increases were monitored by the Wilhelmy method 
using a Whatman’s CH1 filter paper plate and microbalance 31.  All experiments were 
carried out at 20 °C and repeated 4 times. 
Thermodynamic analysis M5-NH2 with lipid monolayers. Compression isotherms 
were generated from monolayers formed from POPG and POPE in the molar ratio 70:30. 
Chloroformic solutions of these lipid molecules (2.5 × 1015) were spread onto a buffer 
subphase (1 × PBS, pH 7.4), the solvent allowed to evaporate for 10 min and the monolayer 
left to stabilize for a further 20 min. The trough barriers were then closed at a speed of 0.22 
nm2 min-1 until monolayer collapse pressure was achieved. Surface pressure changes were 
monitored and plotted as a function of the area per lipid molecule. Corresponding 
experiments were then performed except that M5-NH2 was introduced into the subphase to 
give a final peptide concentration of 6.0 µM. All experiments were carried out at 20 °C and 
repeated 4 times 31. 
Thermodynamic analysis of these isotherms was undertaken and compressibility moduli 
(Cs-1) determined to provide a measurement of the compressional elasticity of monolayers 
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and hence information about the packing of their component molecules. Cs-1 was computed 
according to equation 1 [39]:  
Cs-1 = −𝑨 ( 
𝜹𝝅
𝜹𝑨
 )    (1) 
where π is surface pressure of the monolayer and A represents the area per lipid molecule 
in the monolayer.  
Thermodynamic analysis of these isotherms was also used to determine the Gibbs free 
energy of mixing (ΔGmix) of monolayers, which provides a measure of the relative stability 
associated with the miscibility energetics of their pure lipid components. 
Thermodynamically stable and thermodynamically unstable monolayers are indicated by 
negative and positive values of ΔGmix respectively 33. ΔGmix was computed according to 
equation 2: 
∆𝑮𝒎𝒊𝒙  =  ∫[𝑨𝟏,𝟐 − (𝑿𝟏𝑨𝟏 + 𝑿𝟐𝑨𝟐)]𝒅𝝅      (2) 
where A1,2, is the molecular area occupied by the mixed monolayer, A1, A2 are the area per 
lipid molecule in the pure monolayers of component 1 and 2, X1, X2 are the molar fractions 
of the components and π is the surface pressure. Numerical data were calculated from the 
compression isotherms according to the mathematical method of Simpson 34. 
The membranolytic ability of M5-NH2. The membranolytic ability M5-NH2 was 
determined using a dye release assay 25. Chloroformic solutions of lipid (7.5 mg ml−1) in 
the form of either, POPG and POPE in the molar ratio 70:30 or total lipid extracts from 
membranes of B. subtilis. These solutions were dried under N2 gas and kept under vacuum 
for at least 12 hours to ensure complete removal of the solvent. The resulting lipid films 
were then hydrated with 1 ml of 5.0 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) (pH 7.5) containing calcein (70.0 mM) and the suspension vortexed for 5 min 
before being sonicated for 30 min, which was followed by 3 cycles of freeze-thawing to 
maximize calcein encapsulation. Vesicular encapsulated calcein was then separated from 
the free dye by elution with HEPES (5.0 mM, pH 7.5) down a Sephadex G75 column 
(SIGMA, UK), which had been rehydrated overnight in HEPES (20.0 mM, pH 7.5), NaCl 
(150 mM) and Ethylenediaminetetraacetic acid (EDTA, 1.0 mM). The calcein release assay 
was performed by combining 25 μL of vesicular encapsulated calcein with 50 μL of 10 µM 
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M5-NH2, which was then made up to a final volume of 1 ml with 20.0 mM HEPES, 150.0 
mM NaCl and 1.0 mM EDTA (pH 7.4). The fluorescence intensities of calcein was 
monitored at 20°C using an FP-6500 spectrofluorometer (JASCO, UK), with an excitation 
wavelength of 490 nm and emission wavelength of 520 nm. The fluorescence intensity 
induced by the addition of 10 μL of triton X-100 (10 %, v/v) to vesicular encapsulated 
calcein was taken to represent 100 % dye release and was used to calculate the relative % 
of calcein released from vesicles by M5-NH2. All experiments were repeated 4 times. 
The membrane binding properties of M5-NH2. A fluorescent probe assay was used to 
evaluate the ability of M5-NH2 to bind to membranes 25. SUVs formed from POPG and 
POPE in the molar ratio 70:30 were prepared and fluorescein-phosphatidylethanolamine 
(FPE, 0.5 M) was added to the organic solvent before drying under vacuum overnight to 
create a lipid film.  These films were then hydrated with Tris-HCl (10.0 mM, pH 7.4) and 
EDTA (1.0  mM), followed by freeze-thawing 5 times and extrusion 11 times through an 
Avanti mini-extruder apparatus containing a 0.1 µm polycarbonate filter. Fluorescence was 
recorded using an FP-6500 spectrofluorometer (JASCO, UK), with an excitation 
wavelength of 492 nm, an emission wavelength of 516 nm, and excitation and emission 
slits set to 5 nm.  To investigate the binding of peptide to lipid vesicles, M5-NH2 in the 
range 0 to 325 µM, was added to the FPE-labelled SUVs and the fluorescence monitored. 
The change in fluorescence (ΔF) was then determined as the fluorescence of FPE-labelled 
vesicles in the presence of peptide minus that of FPE-labelled vesicles in the absence of 
peptide. These ΔF values were then plotted against the concentration of M5-NH2 and then 
fitted by non-linear least squares analysis to equation 3:  
∆𝑭 = ∆𝑭𝑴𝒂𝒙  [𝑨]/𝑲𝒅 + [𝑨]    (3) 
Where [A] is the concentration of M5-NH2, ΔF is the change in fluorescence, ΔFMax is the 
maximum change in fluorescence and Kd, is the binding coefficient of the peptide. All 
experiments were repeated 4 times and the average value of ΔF calculated. 
Neutron diffraction localization of M5-NH2 in lipid bilayers. Neutron diffraction 
experiments to determine the disposition of M5-NH2 in lipid bilayers were carried out on 
the V1 neutron membrane diffractometer at BER II, Helmholtz-Zentrum für Materialien 
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und Energie, Berlin 35. Chloroformic solutions (20 mg ml−1) containing POPG and POPE 
in the molar ratio, 70:30 were prepared.  Aliquots (1 ml) of these lipid solutions, and these 
solutions containing either protonated M5-NH2 (3 % molar), or this peptide deuterated at 
leucine 16 of its primary structure, d-M5-NH2-L16 (3 % molar), were individually 
deposited onto quartz microscope slides using an artist’s airbrush.  The slides were then 
placed in a vacuum desiccator for 12 h to remove all traces of chloroform before rehydration 
for 24 h at 25 °C with relative humidity maintained at 98 % using Teflon water baths 
containing saturated potassium sulphate solution in 8 % 2H2O. The scanning procedure 
consisted of sequential θ scans around the predicted Bragg angle for each order.  The 
rocking scans covered the Bragg position θ for the angle θ ± 2°.  Diffraction patterns of the 
prepared samples were measured with up to five orders detected for each sample. The raw 
data from the two dimensional detector were summed to intensity versus 2θ using the V1 
instrumental software 36. The commercial software IGOR Pro (version 4) was used for all 
further data analysis. The lamellar, or bilayer, spacing ‘d’ of each sample was calculated 
by least-square fitting of the observed 2θ values to equation 4, the Bragg equation:  
Nλ = 2d sinθ     (4) 
where N is the diffraction order and λ is the neutron wavelength (4.52 Å). The integrated 
intensities were calculated based upon the Gaussian fit of the experimental Bragg 
reflections. Absorption correction and Lorentz factor were applied and their intensities 
square-rooted to produce structure-factor amplitudes. The phase assignment of each order 
and the relative scaling of the different data sets were determined by contrast variation in 
the aqueous atmosphere by adjusting the molar 2H2O/H2O ratio to 8 %, 20 %, and 50% 
2H2O 36. The scattering length density profiles ρ(z) were then calculated for each sample 
using equation 5: 
ρ(z) = ρ0  + 2/d ∑ ƒ(h) cos (2πhz/d)   (5) 
where ρ0 (z) is the integral density per unit length of the bilayer, ƒ(h) are the scaled structure 
factors and the second term describes the distribution in the scattering lengths across the 
bilayer.   
  
  12 
Results 
The theoretical analysis of M5-NH2. The sequence of M5-NH2 was modelled as a two-
dimensional axial projection and the peptide displayed amphiphilicity with six lysine 
residues and the amide moieties on lysine 1 and leucine 16 generating positive charge on 
the hydrophilic face. (Fig.  1A) and suggesting a preference for binding to anionic 
membrane components 37. The amphiphilicity was quantified by the hydrophobic moment, 
< µH >, with a value of 0.75, which is typical of peptides active at the membrane interface 
29 and consistent with an ability to partition into the membrane 37.  
 
Fig.  1. Theoretical analysis of M5-NH2. M5-NH2 displayed a cationic α-helix, with a hydrophilic 
face rich in lysine residues and a hydrophobic face comprising alanine and leucine residues (Fig.  
1A). The hydrophobic moment for this α-helix was < µH > = 0.75, indicating strong 
amphiphilicity and the potential for high levels of activity at a membrane interface 29. M5-NH2 
showed an amphiphilic profile with - < µH > generally increasing over residues 4 to 13 in the N 
→ C direction, indicating the potential for  hydrophobicity gradient and tilted peptide formation. 
Values of - < µH > increased from circa – 0.8 to – 0.6, consistent with formation of a tilted peptide 
that occupies locations in the upper regions of the membrane (Fig.  1B) 30.  
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The potential of M5-NH2 to form a tilted peptide was investigated by amphiphilic 
profiling using -< µH >, which provides a graphical representation of the hydrophobicity 
gradients possessed by these peptides along their α-helical long axis. This asymmetric 
distribution of hydrophobicity is predicted to cause the parent peptide to penetrate 
membranes at a shallow angle of between 20 and 80, thereby promoting a range of 
membrane destabilizing effects including the disturbance of lipid organisation and the 
compromise of bilayer integrity 30, 37. M5-NH2 exhibited a hydrophobicity gradient with 
values of  - < µH > that generally increased from circa – 0.8 to – 0.6 in the N → C direction 
and which extended over residues 4 to 13 (Fig.  1B). Values of - < µH > of this order are 
consistent with tilted penetration by the peptide into the surface regions of the membrane 
30, 37. This contrasts to the tilted peptide, maximin H5, whose hydrophobicity gradient is 
characterised by much lower values of - < µH > than those of M5-NH2 and appears to 
promote deep penetration of the central core region of membranes 31, 38. 
The antibacterial and membranolytic activity of M5-NH2.  The antibacterial activity of 
M5-NH2 was evaluated against B. subtilis using a standard assay, and the peptide exhibited 
potent action against this organism with an MLC of 8.47 µM. This level of activity is circa 
10 to 15 fold stronger than that generally shown by the peptide towards other bacteria, 
indicating that  B. subtilis is highly susceptible to the action of M5-NH2 19, 20, 22-25. For all 
AMPs, antibacterial activity involves membrane interaction 9, 10, 12 and the calcein release 
assay is frequently used to probe the structure / function relationships involved in these 
interactions 39. Use of this assay showed that M5-NH2 induced 59.3 % leakage of the dye 
in vesicles formed from POPG and POPE in the molar ratio 70:30 and 56.77 % leakage in 
those formed from lipid extracts of membranes from B. subtilis. These levels of calcein 
release show that M5-NH2 is able to induce high levels of permeability in these membrane 
mimics and are typical of strongly membranolytic AMPs, as reported for the antibacterial 
and anticancer action of maximin H5 31, 38. Taken with the high level of toxicity shown by 
M5-NH2 towards B. subtilis, these calcein release data also illustrate the general tendency 
of AMPs to reflect potency in biological action as efficacy in membranolysis 9, 10, 12. 
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The conformational analysis of M5-NH2. CD spectroscopy is commonly used to study 
conformational changes in AMPs, a primary determinant in their antimicrobial action 40. 
Use of this technique showed that for all SUVs studied, M5-NH2 displayed spectra with 
minima at 221 – 222 nm and 209 – 210 nm, and maxima at about 195 nm (Figs 3A and 
3B), characteristic of α-helical structure 31, 38.  Analysis of these spectra showed that M5-
NH2 possessed 32.67 % α-helicity in the case of SUVs formed from POPE and 60.40 % α-
helicity in the case of those formed from POPG (Figs 2A).  In relation to lipid mimics of 
B. subtilis membranes, the peptide exhibited 53.40 % α-helicity in the presence of SUVs 
formed from POPG and POPE in the molar ratio 70:30 and 52.62 % α-helicity in the 
presence of those formed from lipid extract of the latter organism’s membranes (Fig.  2B).  
M5-NH2 is known to be unstructured in aqueous solution 23 and in combination, these 
data indicate that the peptide generally undergoes a conformational rearrangement at a 
membrane interface to adopt α-helical structure. This is enhanced by the presence of PG 
species or anionic lipid in general and is consistent with previous findings 23, 25. Such 
interfacial conformational behaviour is typical of α-helical AMPs and facilitates the 
generation of amphiphilic structures that constitute the membrane interactive forms of these 
peptides 9, 10, 12. 
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Fig.  2. CD spectral analysis of M5-NH2. In the presence of all SUVs examined, M5-NH2 displayed 
spectra with minima at 221 – 222 nm and 209 – 210 nm and maxima at about 195 nm (Figs. 2A 
and2B), which is characteristic of α-helical structure 31, 38. In the case of SUVs formed from POPE 
(grey) and POPG (black), the peptide possessed 32.67 % and 60.40 % α-helicity, respectively (Fig. 
2A). In the presence of SUVs, which acted as lipid mimics of B. subtilis membranes, M5-NH2 
possessed 52.62 % α-helicity in the case of those formed from lipid extract of the organism’s 
membranes and 53.40 % α-helicity in the case of those formed from POPG and POPE in the molar 
ratio 70:30 (Fig.  2B). These data indicated that the peptide has a general ability to adopt α-helical 
structure in the presence of membranes that is enhanced by PG species or the anionic lipid of 
bacterial membranes, a common feature in the action of many AMPs 37. 
The interaction of M5-NH2 with lipid monolayers. Lipid monolayers are highly effective 
for investigating the interaction of AMPs with membranes when precise control over 
membrane composition and compression is required 33. Use of this methodology showed 
that M5-NH2 partitioned into lipid monolayers formed from either POPE or POPG with 
generally similar kinetics, exhibiting very rapid initial rates of insertion over circa five 
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seconds (Fig.  3A). The peptide then inserted into these monolayers at a slower rate until 
maximal surface pressure changes were induced after approximately 500 seconds, 
indicating saturation with M5-NH2. However, these maximal surface pressure changes 
varied widely, with 3.5 mN m-1 observed in the case of monolayers formed from POPE, 
indicating relatively low levels of interaction by the peptide. In contrast, maximal surface 
pressure changes of 11.5 mN m-1 were observed in the case of monolayers formed from 
POPG, indicating high levels of interaction by M5-NH2 (Fig.  3A). In combination, these 
monolayer results clearly reflect the structural amphiphilicity of M5-NH2 (Fig. 1A) and 
reinforce the observation that the peptide has a strong interaction with either PG species or 
anionic lipid, in general 
In relation to lipid mimics of B. subtilis membranes, M5-NH2 exhibited very rapid initial 
rates of insertion over circa five seconds in the case of both, monolayers formed from 
POPG and POPE in the molar ratio 70:30 and those formed from lipid extracted from the 
organism’s membranes (Fig.  3B). However, afterwards, the peptide took circa ten times 
longer to achieve maximal surface pressure changes in monolayers composed of lipid 
extract as compared to the former monolayers (Fig.  3B), which may relate to the greater 
compositional complexity of monolayers formed from naturally occurring B. subtilis 
membranes 41, 42. The maximal surface pressure changes achieved by M5-NH2 were 9.0 
mN m-1 in monolayers formed from POPG and POPE in the molar ratio 70:30 and 8.0 mN 
m-1 in those formed from lipid extract of the organism’s membranes (Fig.  3B). These 
surface pressure changes are consistent with the apolar face of the α-helical peptide 
interacting with the monolayer acyl chain region. Concomitantly, association of the polar 
face of α-helical M5-NH2 with the monolayer head group region would be predicted to 
stabilise these hydrophobic interactions 33. Comparable results have been reported for other 
α-helical AMPs such as aurein 2.5, which kills bacteria using highly membranolytic 
mechanisms of action 43. 
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 Fig.  3. The interaction of M5-NH2 with lipid monolayers. In the case of all monolayers examined, 
M5-NH2 showed high initial rates of insertion prior to achieving maximal surface pressure 
changes. These surface pressure changes were 3.5 mN m-1 in the case of monolayers formed from 
POPE (grey) and 11.5 mN m-1 in the case of those formed from POPG (black) (Fig.  3A), which 
clearly indicated an ability to interact with both zwitterionic and anionic lipid, reflecting the 
structural amphiphilicity of the peptide (Fig.  1A). For monolayers that acted as mimics of B. 
subtilis membranes, M5-NH2 displayed maximal surface pressure changes of 8.0 mN m-1 in the 
case of those formed from lipid extract of the organism’s membranes and 9.0 mN m-1 in the case 
of those formed from POPG and POPE in the molar ratio 70:30 (Fig.  3B). These data clearly 
indicated that the peptide has a general ability to partition into membranes that is enhanced by PG 
species or the anionic lipid of bacterial membranes, a common characteristic in the activity of 
many AMPs 37. 
The membrane binding properties of M5-NH2. Another common approach to 
investigating the interaction of AMPs with membranes is to measure their lipid affinity 
using the fluorescence probe, FPE 44.  This was used to evaluate the ability of M5-NH2 to 
bind to membranes (Fig.  4). In all cases examined, the binding of the peptide to SUVs 
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followed hyperbolic kinetics, with fluorescence rapidly increasing as the concentration of 
M5-NH2 rose. At a concentration of circa 150 μM, changes in fluorescence became 
independent of peptide concentration, indicating that SUVs were saturated with bound M5-
NH2 and no further binding of peptide could take place (Fig.  4). Analysis of these data 
indicated that the peptide bound to SUVs formed from POPG and POPE in the molar ratio 
70:30 with a Kd value of 10.44 µM.  This shows that M5-NH2 would have a high affinity 
for B. subtilis membranes, which is around tenfold stronger than that shown by the peptide 
for membrane mimics of S. aureus 23. 
M5-NH2 also exhibited an affinity for both POPG and POPE (Fig.  4), which reflects the 
amphiphilic nature of the peptide (Fig.  1A). However, M5-NH2 bound POPG with a Kd 
value of 7.46 µM, which is circa two-fold stronger than that shown in the case of POPE 
where a Kd value of 14.7 µM was observed. In combination, these results clearly indicate 
that the peptide has a high affinity for PG species or anionic lipid, in general. These results 
also indicate that binding to B. subtilis membranes is likely to involve both hydrophobic 
interactions and a major contribution from hydrophilic associations. 
 
Fig.  4. Lipid binding affinity analysis of M5-NH2. The lipid affinity of M5-NH2 was measured by 
its Kd value, which was derived from the maximum change in fluorescence induced by the peptide 
(ΔF) in FPE labelled SUVs. M5-NH2 bound SUVs formed from POPE (dashed black) with a Kd 
value of 14.7 µM and POPG (dashed grey) with a Kd value of 7.46 µM, demonstrating an affinity 
for both zwitterionic and anionic lipid, reflecting the structural amphiphilicity of the peptide (Fig. 
1A).  M5-NH2 bound SUVs formed from POPG and POPE in the molar ration 70:30 (black), 
which acted as lipid mimics of B. subtilis membranes, with a Kd value of 10.44 µM. These data 
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indicated that the peptide has a general affinity for membranes that was enhanced by PG species 
or the anionic lipid of bacterial membranes. 
Thermodynamic analysis of M5-NH2 interaction with lipid monolayers. Thermodynamic 
analyses of area-pressure isotherms derived from monolayers are frequently used to inform 
changes in the architecture and properties of membranes induced by their interaction with 
AMPs 33. Use of these analyses for monolayers formed from POPG and POPE in the molar 
ratio 70:30 (Fig.  5) showed that Cs-1 values increased with rising compression pressures, 
both in the presence and absence of M5-NH2 (Table 1) These Cs-1 values lay in the range 
9.16 mN m-1 to 40.37 mN m-1 (Table 1), indicating that the corresponding monolayers were 
generally in the liquid expanded phase and were highly fluid across the compression 
pressure range of 5 mN m-1 to 20 mN m-1 33. For a given compression pressure, the presence 
of M5-NH2 led to reductions in the Cs-1 values of monolayers (Table 1), which indicated 
that their lateral pressure and lipid packing density had decreased. These changes are 
reflected as increased monolayer elasticity and fluidity and are consistent with the 
partitioning of the peptide into these B. subtilis membrane mimics 33. Similar results have 
been reported for other AMPs and, in these cases, changes in monolayer elasticity and 
fluidity have been primarily ascribed to membrane expansion via peptide – lipid head group 
interactions 45.  
 
Fig.  5 Thermodynamic analysis of M5-NH2 interaction with lipid monolayers. Compression 
isotherm analysis of monolayers formed from POPE (grey), POPG (light grey) and POPG and 
POPE in the molar ratio 70:30 (black) in the absence of M5-NH2 (solid lines) and presence of the 
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peptide (dotted lines) were used to generate values of Cs-1 and ΔGmix for lipid mimics of B. subtilis 
membranes. Analysis of these data showed that, for a given compression pressure, the presence of 
M5-NH2 led to reductions in the Cs-1 values of these B. subtilis membrane mimics (Table 1), 
indicating that their lateral pressure and lipid packing density had decreased, consistent with 
partitioning of the peptide 33. These analyses also showed that for a given compression pressure, 
the presence of M5-NH2 changed ΔGmix values from > 0 to < 0 for B. subtilis membrane mimics 
(Table 1), indicating a thermodynamically stabilizing effect 33 that was consistent with the 
promotion of increased membrane fluidity via peptide – lipid head group interactions 45. 
Compression isotherm analysis of monolayers formed from POPG and POPE in the 
molar ratio 70:30 (Fig.  5) was also used to determine values of ΔGmix for these lipid systems 
(Table 1). In the absence of M5-NH2, these ΔGmix values were > 0, increasing from 4.56 to 
20.07 as the compression pressure rose from 5 mN m-1 to 20 mN m-1 (Table 1). These 
results indicated that there were energetically unstable interactions between the individual 
lipid components of these monolayers, consistent with a phase separation 33. However, in 
the presence of M5-NH2, these ΔGmix values were < 0, decreasing from -2.99 to –13.84 
across the same compression pressure range, indicating that there were attractive 
interactions between the individual monolayer components (Table 1). In combination, these 
data show that B. subtilis membrane mimics that were thermodynamically unstable (ΔGmix 
> 0) were rendered  thermodynamically stable (ΔGmix < 0) by interaction with M5-NH2 33. 
Similar thermodynamically stabilizing effects are induced in these membrane mimics by 
other AMPs which were attributed to peptide – lipid head-group interactions that promoted 
increased membrane fluidity, paralleling our Cs-1 data (Table 1) 45. It is well established that 
increases in the elasticity and fluidity of membranes are often associated with thinning of 
the bilayer and are common characteristics of the antibacterial action of AMPs 46. 
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Table 1. Thermodynamic properties of monolayer mimics of B. subtilis membranes 
Surface 
pressure 
π (mN 
m-1) 
POPG and 
POPE in the 
molar ratio 
70:30 
Cs-1 (mN m-1) 
POPG and POPE 
in the molar ratio 
70:30 
∆Gmix (kJ mol-1) 
 - M5-
NH2 
+ M5-
NH2 
- M5-
NH2 
+ M5-
NH2 
5 25.52 9.16 4.56 -2.99 
10 36.12 30.17 10.04 -6.68 
15 37.20 32.98 14.66 -9.86 
20 40.37 34.52 20.07 -13.84 
 
 
 
Neutron diffraction localization of M5-NH2 in lipid bilayers. Neutron scattering in 
conjunction with the substitution of hydrogen by its heavier isotope, deuterium, is 
frequently used to analyse the local structure, dynamics and interactions of multi-
component, biomolecular systems 47. To assess the disposition of M5-NH2 in B. subtilis 
membrane mimics formed from POPG and POPE in the molar ratio 70:30, the N-terminal 
residue, L16, of the peptide was deuterated and its interaction with these membranes 
studied by neutron diffraction (Fig.  6), which is a form of elastic scattering 47. The lamellar 
d-spacings obtained for these lipid membranes were d = 53.6 ± 0.2 Å, in the absence of the 
peptide, d = 51.7 ± 0.2 Å in the presence of M5-NH2 and d = 52.6 ± 0.2 Å in the presence 
of d-M5-NH2-L16. These changes in lamellar d-spacings indicate that the thickness and 
hydration of the bilayers were affected by interaction with the peptide 48.  The structure 
factors from Table 2 were employed to determine neutron diffraction density profiles for 
the interaction of M5-NH2 and d-M5-NH2-L16 with bilayers formed from POPG and POPE 
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in the molar ratio 70:30 (Fig. 6). For these determinations, an 8 % 2H2O contrast was used 
to provide an H2O/2H2O ratio at which the mean neutron scattering length of the water 
mixture was zero 48. The experimentally determined scattering density profiles of samples 
containing either M5-NH2 or d-M5-NH2-L16, scaled to the sum of the respective structure 
factors, were subtracted to reveal the position of the deuterated L16 residue within the 
bilayer. A positive difference between these two profiles was indicated at a distance of 5.5 
± 0.1 Å from the membrane centre (Fig.  6). To determine the label position directly from 
the structure factors, a fit of a Gaussian model to the difference in structure factors in 
reciprocal space was performed 36.  The result indicated that the label position was at 5.7 ± 
0.1 Å from the membrane centre, which is close to that obtained from the difference in 
experimentally determined density profiles. The difference in the fitted density profile, 
calculated with 5 structure factors, is less ‘wavy’ than the difference in the experimentally 
determined profiles, as in this case, the origin is solely the Fourier truncation error. These 
results locate L16 of M5-NH2 within the acyl chain region of the B subtilis membrane 
mimics.  
For scattering density profiles, the water layer thickness of bilayers, dw, is defined by 
twice the distance of the unit cell edge to the position of half of the scattering length 
maximum, zw 36.  For example, the water boundary defined by zw for a leaflet of bilayers 
formed from POPG and POPE in the molar ratio 70:30 in the presence of d-M5-NH2-L16 
is indicated in Fig. 6 by the thin vertical line. Analysis of Fig. 6 showed that for these 
bilayers, dw decreases from 9.2 ± 0.2 Å to 8.4 ± 0.2 Å in the presence of M5-NH2 and 8.6 
± 0.2 Å in the case of d-M5-NH2-L16. The distance between the density peaks 
corresponding to the lipid head-groups in scattering density profiles is indicative of the 
thickness of the bilayer 36 and in the case of those formed from POPG and POPE in the 
molar ratio 70:30, this distance was 36.8 ± 0.2 Å in the absence of the peptide (Fig.  6). 
This distance was decreased to 35.0 ± 0.2 Å in the presence M5-NH2 and to 35.06 ± 0.2  Å 
in the presence of d-M5-NH2-L16, signifying a reduction in the bilayer thickness of around 
1.8 Å. Taken together, these data indicate that the peptide modulates structure in the acyl 
chain region of B. subtilis membranes and induces a membrane thinning effect; this is 
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consistent with the thermodynamic data (Fig.  5). Comparable decreases in bilayer 
thickness have been reported for a number of other membrane thinning AMPs, such as 
magainin 2 and BP100  49. 
 
Fig.  6. Neutron diffraction studies on M5-NH2 / d-M5-NH2-L16 – membrane interactions. 
Neutron scattering density profiles were produced for a transection taken perpendicular to the 
surface of bilayers formed from POPG and POPE in the molar ratio 70:30, which acted as lipid 
mimics of B. subtilis membranes. These bilayers were either in the absence of peptide (dashed 
black), or in the presence of either M5-NH2 (black) or d-M5-NH2-L16 (grey), at 8 % 2H2O. The 
difference between the experimentally determined scattering density profiles of samples with 
either M5-NH2 or d-M5-NH2-L16 (dotted black), and a Gaussian model fitted to the difference in 
structure factors in reciprocal space (dotted grey) 36 revealed the position of the deuterated L16 
residue within the bilayer. In relation to the membrane centre (z = 0 Å 48), a positive difference 
between the experimentally determined profiles was revealed at a distance of z = ± 5.5 ± 0.1 Å, 
and at a distance of z = ± 5.7 ± 0.1 Å for the Gaussian model fitted to the difference in structure 
factors in reciprocal space. In both cases, these differences are attributed to L16 of M5-NH2 
residing within the acyl chain region of the bilayer. The water boundary, zw, for a leaflet of bilayers 
formed from POPG and POPE in the molar ratio 70:30 in the presence of d-M5-NH2-L16 is 
indicated by the thin vertical line. The position of the density peaks corresponding to the lipid 
head-group regions of these bilayers provides information regarding their thickness 36.  The 
distance between these lipid head-groups, or density profile peaks (Dpp), was 36.8 ± 0.2 Å in the 
absence of peptide, which was decreased to 35.0 ± 0.2 Å in the presence M5-NH2 and 35.06 ± 0.2 
Å in the presence of d-M5-NH2-L16, as is indicated above. In combination, these data indicate that 
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the peptide modulates structure in the acyl chain region of B. subtilis membranes. This effect 
decreased the bilayer thickness by circa 1.8 Å, or 5 %, inducing a membrane thinning effect. 
Comparable decreases in bilayer thickness have been reported for a number of other membrane 
thinning AMPs 49.  
 
 Table 2. Experimental structure factors F(h), corrected and scaled, as described in the text 
POPG and POPE 
in the molar ratio 
70:30 
F(1) F(2) F(3) F(4) F(5) 
     
+ M5-NH2 0.498 ± 
0.0017 
-0.254 ± 
0.0040 
-0.215 ± 
0.0030 
-0.033 
±0.0070 
 
+ d-M5-NH2-L16 0.471 ± 
0.0020 
-0.252 ± 
0.0040 
-0.203 ± 
0.0040 
-0.04 ± 
0.0210 
0.03 ±  
0.0130 
Discussion  
By far the biggest group of naturally occurring AMPs are those that adopt amphiphilic 
α-helical conformations.  This form of secondary structure has been used as a template for 
the production of numerous synthetic peptides with potential as antimicrobials 50. A number 
of these AMPs are based on a periodicity of lysine residues alternating with alanine and 
leucine residues that is designed to optimize the levels of amphiphilicity and α-helicity of 
the parent structure (LAK AMPs) 51. The use of these residues minimises production costs 
and LAK AMPs have been employed in a number of capacities, ranging from serving as 
the membrane disrupting domain of targeted pro-apoptotic peptides 52 to enhancing the 
antimicrobial action of sonosensitizers when conjugated with these molecules 53. LAK 
AMPs also serve as potent, broad range antibacterial agents 51 with activity against MDR 
pathogens such as A. baumannii, and the ability to synergize the action of conventional 
antibiotics against these pathogens 54. A major example of LAK AMPs is modelin-5-
CONH2 (M5-NH2) and in the present study, we have sought to investigate mechanisms 
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underpinning the activity of the peptide against B. subtilis 19-25.  Here M5-NH2 was found 
to kill B. subtilis at micromolar levels of peptide (8.47 µM).  Such levels of antibacterial 
activity are desirable when screening peptides for the potential to serve as leads in designing 
therapeutic AMPs 10.  
It is well established that the antibacterial action of all known AMPs involves interaction 
with membranes and M5-MH2 showed a clear ability to interact with those formed from 
the native lipids of B. subtilis (Figs 3B, 4 and 5). However, to gain a deeper understanding 
of these interactions and to enable a more detailed data analysis in compression isotherm 
studies and neutron diffraction investigations (Figs 5 and 6), B. subtilis membranes were 
modelled by synthetic lipid mixes rather than bacterial lipid extracts. The majority of the 
native lipids in B. subtilis membranes are various phosphatidylglycerol (PG) species (70 
%) with the remainder comprising a variety of phosphatidylethanolamine (PE) species 41, 
42. Accordingly, synthetic lipid mimics of B. subtilis membranes were formed from the 
representative PG species, POPG, and the representative PE species, POPE, in the molar 
ratio 70:30. Control experiments established that M5-MH2 showed similar conformational 
behaviour and lipid interactivity between these synthetic lipid mimics and native lipid 
mimics of B. subtilis membranes (Figs 2 and 3). Whilst it is recognised that these synthetic 
systems lack a range of non-lipid components, they are well documented as providing 
information regarding the important role of lipid membrane components in relation to the 
mode of action used by AMPs 33. 
In general, the interaction of AMPs with the bacterial membrane leads to the death of 
these organisms via membranolysis and a number of models have been presented to 
describe this process, such as the barrel stave, toroidal pore, carpet and tilted-type 
mechanisms 37. Based on similarities to these models, a synthesis of the data presented here 
permits a scheme to be constructed that describes the ability of M5-MH2 to kill B. subtilis. 
In the first step of this scheme, the strongly cationic peptide targets anionic components of 
B. subtilis membranes, including PG species. M5-MH2 then binds to these membranes with 
high affinity (Kd = 10.44 µM, Fig.  4) to adopt α-helical structure (> 50 %, Fig.  2B), the 
membrane interactive form of M5-MH2 for this organism. The peptide is strongly attracted 
to anionic lipid or PG species and the major driver of this conformational change is the 
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preponderance of these latter species in the membranes of B. subtilis. These PG species 
show a much stronger propensity to induce α-helical structure in the peptide (> 60 %, Fig. 
2A) as compared to PE species (< 40 %, Fig 2A).  
In the next step of our scheme, the high levels of α-helical structure possessed by the 
peptide in the presence of the organism’s membranes (Fig.  2A) drive it to partition strongly 
into these membranes (Δπ ≥ 8.0 mN m-1, Fig.  3B) and to interact with both their head group 
and hydrophobic core regions (Figs 3B and 6). Neutron diffraction studies clearly showed 
that the N-terminal residue, L16, of M5-MH2 was located around 5.5 Å from the centre of 
B. subtilis membranes and in the acyl chain region of these membranes (Fig.  6). The 
underlying driver of the peptide’s insertion into B. subtilis membranes appears to be the 
high amphiphilicity of the α-helical structure adopted in the presence of these membranes 
(< µH > = 0.75, Fig.  1). Indeed, the strongly α-helical peptide showed very high levels of 
partitioning into membranes formed from PG species (Δπ = 11.5 mN m-1, Fig.  3A). 
However, the loss of amphiphilic α-helical structure by M5-MH2 (> 20 %, Fig. 2A) in the 
presence of membranes formed from PE species led to around a threefold reduction in the 
ability of the peptide to partition into these membranes (Δπ = 3.5 mN m-1, Fig.  3A). These 
early steps in the interactions of the peptide with B. subtilis membranes are typical of α-
helical AMPs with activity at the interface and are common to most models used to describe 
the membrane interactions of thee peptide 37. It is generally accepted that the exothermic 
action of α-helix formation contributes strongly to the enthalpy driven mechanisms of 
membrane insertion used by these AMPs 55.  
The partitioning of M5-NH2 into B. subtilis membranes promotes membrane thinning 
effects and this was directly demonstrated by neutron diffraction studies where insertion by 
the peptide was shown to decrease membrane thickness by circa 1.8 Å or 5 % of its width 
(Fig.  6). Insertion by M5-NH2 was also found to promote increases in the surface area (Cs-
1 ↓, Table 1) and fluidity (ΔGmix > 0 → < 0, Table 1) of  B. subtilis membranes, which is 
consistent with a thinning effect 46. Similar results have been reported for other α-helical 
AMPs, such as magainin 2, and in these cases, membrane thinning effects have resulted 
from the insertion of these peptides into the membrane with their α-helices orientated 
parallel to the lipid surface 49, 56. Several studies have suggested that M5-NH2 may also 
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partition horizontally into bacterial membranes 23-25, which could help explain the 
membrane thinning effect observed for the interaction of the peptide with membranes of B. 
subtilis (Table 1, Fig.  6). Indeed, it would seem that horizontally partitioning into these 
membranes would be aided by the even distribution of positive charge along the α-helical 
long axis of the peptide (Fig.  1A) 23-25. Consistent with the high affinity of M5-NH2 for PG 
species (Kd = 7.46 µM, Fig.  4), adopting this orientation would allow the peptide’s lysine 
groups (Fig.  1A) to interdigitate with the head groups of these species (Fig.  6). Indeed, the 
membranes of this organism include very high levels of diphosphatidylglycerol 41, 42, and it 
is well established that anionic moieties in the head group of this PG species are far more 
accessible to AMPs than those of other bilayer lipids 57. Horizontally partitioning into the 
membranes of B. subtilis, would also help drive penetration of the peptide’s alanine and 
leucine residues (Fig. 1A) into the hydrophobic core region of the bilayer, given the affinity 
of M5-NH2 for zwitterionic lipid (Kd = 14.7 µM, Fig. 4). Neutron diffraction studies showed 
that the membrane thinning ability of the peptide involved modulating the structure of the 
acyl chain region by its N-terminal residue, L16 (Fig. 6). Presumably, this action would 
promote the relaxation of acyl chains and lower the order of these lipid tails, as reported for 
other membrane thinning AMPs 49, 56. 
In the latter stages of our putative scheme for the ability of M5-MH2 to kill B. subtilis, 
membrane insertion and thinning effects by the peptide induce high levels of 
membranolysis (> 55 %), resulting in the death of the organism. Based on the data presented 
here, it is not possible to definitively assign the antibacterial action of M5-NH2 to any 
particular model of membrane interaction. Given the relatively short length of the peptide, 
it seems unlikely that it would be able to form a membrane spanning pore, such as the barrel 
stave model proposed for a number of AMPs 37. However, the mode of membrane 
partitioning shown here for the peptide is often associated with the toroidal pore and carpet 
models 37, and these models have previously been predicted to describe the antibacterial 
action of M5-MH2 23-25. According to the first of these models, horizontal insertion and 
thinning by the peptide would destabilize the integrity of B. subtilis, membranes and lead 
to lysis through the generation of transmembrane channels formed by the intercalation of 
reorientated M5-MH2 molecules with lipid.  In the second of these models, a high density 
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of the horizontally orientated peptide would accumulate on the surface of B. subtilis 
membranes, which would promote thinning and dissolution of the bilayer via a detergent-
like action that does not involve channel formation 37. Neutron diffraction studies have 
revealed other mechanisms for the lysis of bilayers by horizontally orientated AMPs 
involving membrane thinning but not leading to pore or channel formation, such as that 
recently described for aurein 1.2. The binding of the peptide to membranes induced 
membrane thinning, accompanied by a major redistribution of PG species in the outer 
leaflet that appeared to promote the formation of complexes between lipid and aurein 1.2 
and the compromise of membrane integrity 58. A further possibility based on the 
architecture of M5-MH2 may be that the mode of membrane partitioning used by the 
peptide leads to the use of a tilted-type mechanism. The peptide shows the potential to form 
α-helical structure with a hydrophobicity gradient that increases towards the N-terminal 
residue, L16, of M5-MH2 (Fig.  1B) and this form of secondary structure is a defining 
characteristic of tilted peptides that promotes their oblique membrane insertion 30, 37. 
Clearly, the lysis of B. subtilis membranes by a tilted mechanism would be consistent with 
the residence of L16 in the acyl chain region of these membranes (Fig.  6). Lysine residues 
possessed by the peptide could also play a role in promoting tilted membrane penetration 
via the snorkelling mechanism, which would allow the amine groups of these residues to 
remain associated with the lipid head-group region of membranes. Concomitantly, their 
long hydrocarbon side chains extend into the membrane’s hydrophobic region, permitting 
deeper levels of penetration by M5-MH2, as reported for other AMPs that appear to use this 
structure to facilitate their antibacterial action 59.  Taken in combination, these observations 
suggest that the use of a tilted mechanism by M5-NH2 to lyse the membranes of B. subtilis 
would involve roles for both PE species and PG species in relation to orientating the peptide 
and modulating the overall effect of its action on lipid organisation and membrane 
architecture. These observations also reinforce the view that to fully characterise the 
antimicrobial action of AMPs, it is necessary to consider the properties of both of these 
peptides and their target membranes 37. 
As a final comment, it is interesting to note that B. subtilis shows historical similarity to 
A. baumannii, in that it was first isolated from soil over a century ago and is generally 
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considered to be non-pathogenic 60. However, since the 1960s, strains of B. subtilis have 
been responsible for a number of serious infections, generally in individuals who are 
critically ill or immunocompromised 61, 62. A very recent study, reported that the organism 
is increasingly prevalent in hospitalized patients and is sufficiently equipped with virulence 
mechanisms to behave as a human pathogen. It has been recommended that the 
identification of B. subtilis and other members of this genus should be routinely performed, 
particularly when samples derive from patients who are immunocompromised or have a 
pre-existing disease condition 63. B. subtilis is also commonly found in probiotic 
formulations and there are now growing concerns about the potential of this organism and 
other species of its genus for virulence when used as a dietary supplement 62-64. Moreover, 
the resistance of B. subtilis to antibiotics has been demonstrated 62 and it is becoming 
increasingly clear that it possesses the ability to resist AMPs; this would seem to make the 
development of M5-MH2 as an agent against the organism timely 65, 66. Indeed, B. subtilis 
may only be one example of an emerging problem which, for example, appears to include 
bacteria of the genus, Lactobacillus, another group of Gram-positive organisms used as 
probiotics 67. These bacteria are generally considered to be harmless but strains are 
emerging with pathogenic relevance to elderly and immunocompromised patients 68, as in 
a recent case of acute cholecystitis caused by vancomycin-resistant Lactobacilli 69.  
Conclusion 
In summary, M5-NH2 is a synthetic antibacterial agent with very low levels of 
haemolysis 26, and here it has been shown that the peptide has a potent ability to kill B. 
subtilis via membranolytic modes of action. Potentially, this action could be facilitated by 
a number of mechanisms, particularly tilted peptide formation: indeed, the data presented 
here could support the use of a recently reported, novel, tilted-type antibacterial 
mechanism. Using this mechanism, AMPs accumulate in the outer leaflet of the bacterial 
membrane and form pore-like structures by inserting in an oblique orientation. The 
resulting shallow pores promote rapid membrane thinning, leading to progressive 
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disintegration and exfoliation of the outer leaflet at the sites of pore formation, which then 
induces cell death 70.  
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